Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Endocrinology

Standard of Care: Managing Your AKT2-Related FPLD

At a Glance

AKT2-related familial partial lipodystrophy is managed with an individualized plan combining dietitian-guided nutrition and activity with medicines for blood sugar and triglycerides. Some people with severe disease and very low leptin may be considered for metreleptin.

Managing AKT2-related FPLD requires a “team-based” approach. Because the condition affects your blood sugar, fats, liver, and sometimes your heart, your care team should ideally include an endocrinologist, a specialized dietitian, and potentially a cardiologist or hepatologist [1][2].

There is no “one-size-fits-all” pill for AKT2. Instead, treatment is tailored to your phenotype—the specific way the condition shows up in your body [1][3].

Importantly, the need for these treatments is not a reflection of personal blame. The metabolic complications of AKT2 are driven by genetic signaling errors, not by a lack of willpower. Diet and exercise manage the symptoms, but they do not “cure” the underlying biology.

The Foundation: Nutrition and Activity

Lifestyle changes are not just “good advice” in FPLD—they are a critical part of your medical treatment. Because your body cannot store excess energy as fat in the normal way, avoiding “energy overflow” is essential [1].

  • Dietary Fat Restriction: When triglycerides are very high, your doctor may recommend a specialized diet to reduce the “load” of fat entering your bloodstream and liver [4][1]. You should work with a specialized dietitian to set an individualized target. Do not attempt a very-low-fat or very-low-calorie diet on your own, as you still need essential fatty acids and nutrients.
  • Avoiding Refined Sugars: High-sugar foods can spike your insulin and trigger your liver to produce even more fat [1].
  • Physical Activity: Regular exercise helps your muscles process sugar and fat directly, which supports your overall metabolic health alongside your treatments [1][5].

Managing Blood Sugar (Diabetes)

If lifestyle changes are not enough to keep your HbA1c (average blood sugar) in a healthy range, your doctor may prescribe medications. Never start, stop, or withhold these medications without consulting your treating clinician.

  • Metformin: Often the first-line medication for adults. It helps your liver produce less sugar and makes your body slightly more sensitive to the insulin you already have [5][3].
  • Insulin: Some people with AKT2 variants require very high doses of insulin because of their extreme resistance. While high insulin levels can occasionally contribute to fat accumulation in unaffected areas like the face and neck, insulin is vital for controlling dangerous blood sugar levels and should never be stopped without medical advice [2][3].
  • GLP-1 Agonists (e.g., Liraglutide): Newer medications like GLP-1 agonists have shown promise in small studies of FPLD patients, helping to lower blood sugar and triglycerides [6][7].
  • SGLT2 Inhibitors: These help the kidneys flush excess sugar out through urine. While useful, they must be used with caution due to a rare risk called Euglycemic Diabetic Ketoacidosis (DKA), especially if you are ill, fasting, or dehydrated. You must have explicit “sick day rules” from your doctor on when to hold this medication [8].

Managing Blood Fats (Triglycerides)

Aggressive management of lipids is vital to prevent pancreatitis (painful inflammation of the pancreas) and protect your heart [9][4].

  • Statins: These are primarily used to lower LDL (bad) cholesterol and reduce the risk of heart attacks [9][10].
  • Fibrates and Fish Oil: Prescription-strength fibrates and highly purified omega-3 fatty acids (fish oil) are used specifically to bring down high triglyceride levels [9][4].

Specialized Treatment: Metreleptin

Metreleptin is a synthetic version of leptin, a hormone naturally produced by fat cells. In people with FPLD, fat loss means they often don’t have enough leptin, which tells the brain the body is “starving” even when blood sugar is high [2][11].

  • Who is it for? While approved in the US primarily for generalized lipodystrophy, it may be considered off-label for selected FPLD patients who have very low leptin levels and severe metabolic disease that hasn’t responded to other treatments [1][12].
  • Important Context: Low leptin alone does not automatically qualify a patient for this treatment. Access, variable response rates in partial lipodystrophy, and risks (such as the development of neutralizing antibodies) require extensive specialist discussion [12][3]. For the right patient, metreleptin can significantly lower triglycerides and improve blood sugar control [11][13].

Summary of Common Medications

Medication Class Example Primary Goal
Biguanides Metformin Lower blood sugar/improve insulin sensitivity [5].
Fibrates Fenofibrate Lower high triglycerides to prevent pancreatitis [9].
GLP-1 Agonists Liraglutide Improve blood sugar and potentially lower triglycerides [6].
Leptin Analog Metreleptin Replace missing leptin to improve overall metabolism [2].

Common questions in this guide

What is the usual treatment approach for AKT2-related FPLD?
Treatment is individualized according to how AKT2-related FPLD affects your blood sugar, triglycerides, liver, heart, and fat distribution. Care often combines dietitian-guided nutrition and physical activity with medicines chosen by an endocrinologist and other specialists when needed.
Can metformin or insulin help manage AKT2-related FPLD?
Metformin is often used first for adults because it can reduce sugar production by the liver and improve insulin sensitivity. Some people have severe insulin resistance and need high doses of insulin, which should never be started, reduced, or stopped without medical guidance.
What diet changes may help lower triglycerides in FPLD?
A specialized dietitian can set an individualized plan, especially when triglycerides are very high. The plan may limit dietary fat and refined sugars, but very-low-fat or very-low-calorie diets should not be attempted without supervision because essential nutrients are still needed.
When might metreleptin be considered for partial lipodystrophy?
Metreleptin may be considered off-label for selected people with partial lipodystrophy who have very low leptin levels and severe metabolic disease that has not responded to other treatments. Low leptin alone is not enough, and specialist review is needed because responses vary and neutralizing antibodies can develop.
What should I know before taking an SGLT2 inhibitor with AKT2-related FPLD?
SGLT2 inhibitors can lower blood sugar but rarely cause diabetic ketoacidosis even when blood sugar is not very high. Illness, fasting, and dehydration can increase this risk, so your clinician should give you clear sick-day instructions about when to hold the medicine and seek help.
How are high triglycerides treated in AKT2-related FPLD?
High triglycerides may be treated with dietary changes, fibrates, and prescription-strength omega-3 fatty acids to reduce the risk of pancreatitis. Statins are mainly used to lower LDL cholesterol and help protect the heart, and your clinician may recommend them based on your overall risk.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my fasting leptin level low enough that I might qualify for metreleptin therapy?
  2. 2.Given my AKT2 variant, is metformin still the best first-line option for my insulin resistance?
  3. 3.What specific dietary changes should I implement with a dietitian to help lower my triglycerides?
  4. 4.If we start an SGLT2 inhibitor, what are my 'sick day rules' to prevent DKA?
  5. 5.Should I be on a statin even if my LDL ('bad') cholesterol looks normal, to protect my heart?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.

    Brown RJ, Araujo-Vilar D, Cheung PT, et al.

    The Journal of clinical endocrinology and metabolism 2016; (101(12)):4500-4511 doi:10.1210/jc.2016-2466.

    PMID: 27710244
  2. 2

    Lipodystrophy for the Diabetologist-What to Look For.

    Patni N, Garg A

    Current diabetes reports 2022; (22(9)):461-470 doi:10.1007/s11892-022-01485-w.

    PMID: 35821558
  3. 3

    Systematic review of genotype-stratified treatment for monogenic insulin resistance.

    Semple RK, Patel KA, Auh S, et al.

    medRxiv : the preprint server for health sciences 2023; doi:10.1101/2023.04.17.23288671.

    PMID: 37205502
  4. 4

    A Comprehensive Update on the Chylomicronemia Syndrome.

    Goldberg RB, Chait A

    Frontiers in endocrinology 2020; (11()):593931 doi:10.3389/fendo.2020.593931.

    PMID: 33193106
  5. 5

    Lipodystrophic syndromes: From diagnosis to treatment.

    Sollier C, Vatier C, Capel E, et al.

    Annales d'endocrinologie 2020; (81(1)):51-60 doi:10.1016/j.ando.2019.10.003.

    PMID: 31982105
  6. 6

    Safety and effectiveness in an uncontrolled setting of glucagon-like-peptide-1 receptor agonists in patients with familial partial lipodystrophy: Real-life experience from a national reference network.

    Lamothe S, Belalem I, Vantyghem MC, et al.

    Diabetes, obesity & metabolism 2025; (27(4)):1815-1825 doi:10.1111/dom.16175.

    PMID: 39829337
  7. 7

    Metabolic Improvements With Tirzepatide in Lipodystrophy: A Novel Option?

    Meral R, Celik Guler M, Kaba D, et al.

    Diabetes care 2025; (48(5)):756-762 doi:10.2337/dc24-2408.

    PMID: 40063619
  8. 8

    Clinical Effects of Sodium-Glucose Transporter Type 2 Inhibitors in Patients With Partial Lipodystrophy.

    Bansal R, Cochran E, Startzell M, Brown RJ

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2022; (28(6)):610-614 doi:10.1016/j.eprac.2022.03.006.

    PMID: 35301125
  9. 9

    Advances in the care of lipodystrophies.

    Shamsudeen I, Hegele RA

    Current opinion in endocrinology, diabetes, and obesity 2022; (29(2)):152-160 doi:10.1097/MED.0000000000000695.

    PMID: 34839327
  10. 10

    Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease.

    Hussain I, Patni N, Garg A

    Pathology 2019; (51(2)):202-212 doi:10.1016/j.pathol.2018.11.004.

    PMID: 30595509
  11. 11

    Efficacy of Metreleptin Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants.

    Sekizkardes H, Cochran E, Malandrino N, et al.

    The Journal of clinical endocrinology and metabolism 2019; (104(8)):3068-3076 doi:10.1210/jc.2018-02787.

    PMID: 31194872
  12. 12

    Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.

    Diker-Cohen T, Cochran E, Gorden P, Brown RJ

    The Journal of clinical endocrinology and metabolism 2015; (100(5)):1802-10 doi:10.1210/jc.2014-4491.

    PMID: 25734254
  13. 13

    Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real-life experience from a national reference network.

    Mosbah H, Vantyghem MC, Nobécourt E, et al.

    Diabetes, obesity & metabolism 2022; (24(8)):1565-1577 doi:10.1111/dom.14726.

    PMID: 35445532

This page explains treatment options for AKT2-related FPLD for informational purposes only and does not replace medical advice. Work with your endocrinologist and care team before changing your diet, insulin, or any other medication.

Get notified when new evidence is published on AKT2-related familial partial lipodystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.